Pre-diagnostic aspirin use and mortality after breast cancer
- 96 Downloads
Whether aspirin or other nonsteroidal anti-inflammation drug (NSAID) use is associated with mortality following breast cancer remains unclear. Consideration of use patterns and interaction with obesity may help to clarify the inconsistent results.
Pre-diagnosis NSAID use, weight, and height were assessed ~ 3 months after diagnosis through in-person interviews with a population-based cohort of 1,442 women with first primary breast cancer. Vital status was determined through the national death index after ~ 18 years of follow-up (N = 237/597 breast cancer-specific/all-cause deaths). We used Cox proportional hazards regression to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Multiplicative interaction by body mass index (BMI) was evaluated using the likelihood ratio test.
Ever aspirin use was inversely associated with breast cancer-specific mortality (HR 0.87, 95% CI 0.59–1.29), but positively associated with all-cause mortality (HR 1.21, 95% CI 0.99–1.48); the CIs included the null values. The HRs, however, were more pronounced for the highest level of duration, frequency, regularity, and timing for all-cause, but not breast cancer-specific mortality. Interactions with BMI revealed no significant heterogeneity (pinteraction = 0.37 and pinteraction = 0.36, respectively).
Pre-diagnosis aspirin use was not strongly associated with mortality following breast cancer. The all-cause mortality associations, however, were slightly stronger when we considered patterns of use.
KeywordsBreast cancer Mortality Aspirin NSAIDs Obesity Body mass index
The study was supported in part by grants from the National Cancer Institute and the National Institute of Environmental Health Sciences (UO1CA/ES66572, U01CA66572).
- 1.American Cancer Society (2017) Cancer facts & figures 2017. American Cancer Society, AtlantaGoogle Scholar
- 5.Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prevent 11(12):1586–1591Google Scholar
- 28.CDC. (2014) National Death Index [Internet] Available http://www.cdc.gov/nchs/ndi.htm. Accessed 12 April 2016)
- 29.Collett D (2003) Modelling survival data in medical research. Chapman & Hall/CRC Press LLC, Boca RatonGoogle Scholar
- 30.Allison P (2010) Survival analysis using SAS: a practical guideGoogle Scholar
- 37.Murray LJ, Cooper JA, Hughes CM, Powe DG, Cardwell CR (2014) Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case–control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res 16(2):R34CrossRefPubMedPubMedCentralGoogle Scholar